Literature DB >> 24768533

The Intermountain Risk Score predicts mortality in trauma patients.

Sarah Majercik1, Stacey Knight2, Benjamin D Horne3.   

Abstract

PURPOSE: Intermountain Risk Score (IMRS) uses the admission complete blood count and basic metabolic profile to predict mortality. Intermountain Risk Score has been validated in medical patients but has not been evaluated in trauma. This study tested whether IMRS is predictive of mortality in a trauma population at a level I trauma center.
METHODS: Admitted trauma patients with complete blood count and basic metabolic profile from October 2005 to December 2011 were evaluated. Thirty-day and 1-year IMRS were calculated using multivariable modeling. Mortality was determined using the medical record and Social Security Administration death data.
RESULTS: Three thousand six hundred thirty-seven females and 5901 males were evaluated. Intermountain Risk Score was highly predictive of death at 30 days (c-statistics, c = 0.772 for females; c = 0.783 males) and 1 year (c = 0.778 for females; c = 0.831 males). Cox regression analysis, adjusted for injury severity score, blunt vs penetrating, and length of stay, showed increased mortality risks among patients in the moderate- and high-risk IMRS-defined groups at both 30 days and 1 year, with hazard ratios ranging from 4.96 to 57.88 (all P < .001).
CONCLUSION: Intermountain Risk Score strongly predicts mortality in trauma patients at this single level I trauma center. The ability to accurately determine a patient's mortality risk at admission makes IMRS a potentially clinically important tool.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intermountain risk score; Mortality; Scoring systems; Trauma

Mesh:

Year:  2014        PMID: 24768533     DOI: 10.1016/j.jcrc.2014.03.016

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  4 in total

1.  Predicting postdischarge hospital-associated venous thromboembolism among medical patients using a validated mortality risk score derived from common biomarkers.

Authors:  Lindsey Snyder; Scott M Stevens; Masarret Fazili; Emily L Wilson; James F Lloyd; Benjamin D Horne; Joseph Bledsoe; Scott C Woller
Journal:  Res Pract Thromb Haemost       Date:  2020-05-20

2.  Comparative evaluation of the clinical laboratory-based Intermountain risk score with the Charlson and Elixhauser comorbidity indices for mortality prediction.

Authors:  Gregory L Snow; Joseph R Bledsoe; Allison Butler; Emily L Wilson; Susan Rea; Sarah Majercik; Jeffrey L Anderson; Benjamin D Horne
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

3.  The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease.

Authors:  Benjamin D Horne; Matthew J Hegewald; Courtney Crim; Susan Rea; Tami L Bair; Denitza P Blagev
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-20

4.  Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort.

Authors:  Benjamin D Horne; Joseph R Bledsoe; Joseph B Muhlestein; Heidi T May; Ithan D Peltan; Brandon J Webb; John F Carlquist; Sterling T Bennett; Susan Rea; Tami L Bair; Colin K Grissom; Stacey Knight; Brianna S Ronnow; Viet T Le; Edward Stenehjem; Scott C Woller; Kirk U Knowlton; Jeffrey L Anderson
Journal:  BMJ Open       Date:  2022-03-24       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.